Brand | Exbio |
Product type | Primary antibodies |
Reactivity | Human, Mouse |
Clonality | Monoclonal |
Brand: | Exbio |
Product no.: | 11-755-C025 |
Product type: | Primary antibodies |
Host species: | Mouse |
Product name: | Mouse Monoclonal to CD266 / TWEAK R |
Antigen: | CD266 / TWEAK R |
Clonality: | Monoclonal |
Clone: | ITEM-4 |
Isotype: | IgG2b |
Immunogen: | human CD266-transfected P815 cells |
Format: | purified |
Specificity: | The mouse monoclonal antibody ITEM-4 recognizes CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis. |
Categories: | Apoptosis (Rodent), CD and Related Antigens & MHC (Rodent), Apoptosis (Human), CD and Related Antigens (Human) |
Concentration: | 1 mg/ml |
Storage buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
Storage / stability: | Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label. |
Background: | CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential. |
Purity: | > 95% (by SDS-PAGE) |
Purification: | Purified by protein-A affinity chromatography |
Product specific references: | *Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1;185(3):1593-605. , *Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8., *Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7(10):e47440., *Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108 |
Related products: | - Mouse Monoclonal to CD273 / PD-L2 - Mouse Monoclonal to CD27 - Mouse Monoclonal to CD271 / NGFR |
Shipping condition: | Room temperature |